Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.
| Source | Count | Share | Status |
|---|---|---|---|
| Europe PMC | 2,560 | 64.5% | Active |
| PubMed | 302 | 7.6% | Active |
| ClinicalTrials.gov | 287 | 7.2% | Active |
| OpenAlex | 264 | 6.7% | Active |
| PsyArXiv | 216 | 5.4% | Active |
| Crossref | 161 | 4.1% | Active |
| bioRxiv | 142 | 3.6% | Active |
Most recently published records currently stored in SQLite.
Neuropsychopharmacology Reports · 2026-08-31
The Brown University Psychopharmacology Update · 2026-07-31
ClinicalTrials.gov · 2026-07-01
Journal of Drug Issues · 2026-06-30
ClinicalTrials.gov · 2026-06-30
The Brown University Psychopharmacology Update · 2026-06-30
The Brown University Psychopharmacology Update · 2026-06-30
Journal of Affective Disorders Reports · 2026-06-30
Palliative medicine · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
ABSTRACT Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), t...
A Phase 1 trial comprising 15 patients has found that repeated high-dose administration of psilocybin was more effective than low-dose psilocybin or placebo in reducing symptoms of obsessive-compulsive disorder (OCD). Psilocybin was generally well-tolerated, with no reports of serious adverse events.
Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-y...
Patients with treatment-resistant depression who received psilocybin-assisted psychotherapy showed clinically meaningful improvement in depressive symptoms relative to placebo, a Phase 2b trial has found. However, the study did not show a significant effect on the primary outcome of treatment response 6 weeks after the first of two doses of psilocybin. Study...
Treatment-resistant depression (TRD) remains a major clinical challenge and is typically defined as the persistence of depressive symptoms despite at least two adequate antidepressant trials. Individuals with TRD experience substantial morbidity, impaired functioning, and elevated suicide risk, highlighting the need for therapeutic strategies beyond incremen...
Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models i...
This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studi...
Background: This systematic review and meta-analysis evaluates the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for adults with major depressive disorder (MDD). Methods: A PROSPERO-registered search (CRD42024561979) of CENTRAL, Scopus, PsycINFO, and MEDLINE (2010-2024) identified clinical trials assessing PAP. Risk of bias was assessed usin...
Purpose This paper aims to examine evolving practices and discourses surrounding psilocybin mushrooms on an online drug forum. Situating use within hybrid digital and ecological contexts, it traces shifts in user engagement before and after the 2020 COVID-19 pandemic to contextualize localized realities of the contemporary psychedelic renaissance. Design/met...
Abstract Psilocybin induces profound alterations in consciousness, yet prevailing neural models often describe a monolithic change in brain connectivity that may not fully capture the multifaceted nature of the psychedelic state. To test the hypothesis of a composite neural state, this study applied a data-driven framework, Connectome Independent Component A...
A single dose of psilocybin may provide rapid relief for people with major depressive disorder (MDD), with benefits emerging within days and lasting for several weeks, according to a randomized clinical trial published May 15 in JAMA Network Open. Researchers of the study, “Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Ran...
